Thymulin Dosage in the Research Literature
thymulin dosage as used in preclinical models: concentrations, routes, and study durations indexed from the peer-reviewed literature. No validated human dosing protocol exists.
No validated human pharmacokinetic data exist for thymulin administered by any common route. All dosage parameters on this page are drawn from preclinical animal models and in vitro studies. Human applications cannot be inferred from preclinical data without controlled clinical trials.
Thymulin Dosage in Preclinical Models
| Study / Model | Dose | Route | Species |
|---|---|---|---|
| Safieh-Garabedian 2002 — pain/inflammation[6] | 1–200 μg/rat; 25 μg intraplantar |
IP; intraplantar | Sprague-Dawley rat |
| Saade 2003 — neuropathic pain[7] | 0.25–50 μg/rat |
IP | Sprague-Dawley rat |
| Safieh-Garabedian 2003 — neuroinflammation[8] | 0.1, 0.5, 1 μg in 5 μL |
ICV | Sprague-Dawley rat |
| Lunin 2008 — cytokine suppression[9] | 15 μg/100g BW |
IP | NMRI mouse |
| Lunin 2019 — EAE nanoparticle[13] | 1.5 mg/kg (PBCA-encapsulated) |
IP ×every other day ×25 d | SJL/J mouse |
| Oliver & Marsh 2003 — avian NK cells[10] | 10 ng/100g; 50 ng/100g |
Injection | K-strain chicken |
| Wise & Ford 1999 — reproductive/endocrine[14] | 4.4, 44.4, 444.4 ng/kg |
IV | White composite boar |
| Hadley 1997 — pituitary cells[11] | 0.5–50 pM (max effect 10 pM) |
In vitro perifusion | Rat anterior pituitary |
| Vickers 2017 — hair pilot[17] | Zinc-thymulin topical spray (concentration not fully detailed) | Topical scalp | Human (n=18) |
At 25 μg intraplantar, PAT (thymulin analogue) pain thresholds returned to control levels and showed superior potency to KDP analogues at 10-fold lower doses.[6] In neuropathic pain models, 0.25–50 μg/rat IP produced peak inhibition 1–2 hours post-treatment in both CCI and SNI models.[7]
Half-Life and Stability
No definitive pharmacokinetic study characterizing thymulin’s half-life in human plasma exists in the peer-reviewed literature. Related thymic nonapeptides have short plasma half-lives — the thymus immunosuppressive pentapeptide (TIPP) has a reported half-life of approximately 6 minutes in mice, suggesting swift renal clearance for unmodified small peptides.
Stability requires zinc at physiological pH (7.4); activity drops to zero below pH 6.0.[1] Zinc chelation (EDTA) abolishes activity in vitro. The short plasma half-life problem motivated two delivery-engineering approaches in the research literature:
- PBCA nanoparticle encapsulation (Lunin et al. 2019) — designed to extend blood half-life and improve CNS penetration.[13]
- Adenoviral gene therapy (Reggiani et al. 2006) — a single intramuscular injection of RAd-metFTS vector restored serum thymulin for 110+ days in mice and 130+ days in rats by creating a persistent ectopic secreting source.[12]
These approaches were motivated precisely by the insufficient duration of effect from direct peptide administration — relevant context for interpreting any protocol that assumes sustained systemic exposure from unmodified thymulin.
Administration Route in Research Protocols
Published thymulin administration protocols use the following routes, indexed by study:
- Intraperitoneal — most common rodent route: Lunin 2008,[9] Lunin 2019,[13] Safieh-Garabedian 2002,[6] Saade 2003[7]
- Intravenous — boar reproductive studies (Wise & Ford 1999)[14]
- Intracerebroventricular — neuroinflammation models (Safieh-Garabedian 2003,[8] Safieh-Garabedian 2011[15])
- Intramuscular — gene therapy vector delivery (Reggiani 2006)[12]
- Topical spray — zinc-thymulin scalp application in the hair follicle pilot study (Vickers 2017); water-based formulation synthesized via Fmoc protocol[17]
- In vitro organ/cell culture — pituitary perifusion,[11] thymic explant cultures,[5] testicular tissue incubation[14]
Comparative bioavailability between IM and SC routes has not been characterized in any human or animal pharmacokinetic study for thymulin.
Thymulin Safety Profile in Preclinical Studies
Preclinical models report minimal adverse effects at studied concentrations. In the mouse cytokine study (Lunin 2008), no adverse events were noted at 15 μg/100g IP.[9] In the EAE nanoparticle study (Lunin 2019), no adverse systemic effects were reported in the PBCA-thymulin group at 1.5 mg/kg every other day for 25 days.[13] In the pilot hair study (Vickers 2017), no adverse systemic effects were reported in 18 subjects over 4–10 months of topical application.[17]
Human safety data are limited. No IND or NDA for the synthetic thymulin nonapeptide has been identified with the FDA. No Phase 2 or Phase 3 trials are registered on ClinicalTrials.gov.
The bidirectional dose-response observed in the NK cell study — low-dose enhancement vs. high-dose suppression[10] — is a notable preclinical signal that underscores the importance of model-specific dosing precision in any thymulin research protocol.
Onset Timeline in Preclinical Immune Studies
Observable T-cell parameter changes were measured at 10 days post-infection in the avian NK cell study.[10] In the PAT analgesic studies, peak inhibition of hyperalgesia was recorded 1–2 hours post-treatment.[7] In the EAE nanoparticle study, disease severity reduction was observed over the 25-day treatment period, with progressive improvement in clinical score.[13]
No definitive onset-to-effect timeline for immune reconstitution in humans can be drawn from available preclinical data. Timing is species-, model-, and dose-dependent across the literature.
Thymulin in Combination: Studied Stacks
Zinc (structural co-factor, not a stack)
Zinc is not a pharmacological stack partner — it is a structural requirement for thymulin bioactivity. Adequate zinc status is a prerequisite for endogenous thymulin function. Human studies confirm that zinc deficiency abolishes thymulin activity and repletion restores it.[4]
Epithalamin / Epitalon (longevity bioregulator research)
Russian bioregulator research (Khavinson & Morozov 2003) studied thymalin + epithalamin as a combination in elderly patients (n=266, >60 years, 6-year follow-up). Thymalin alone was associated with a 2.0–2.1-fold reduction in mortality; combined with Epithalamin, a 4.1-fold reduction.[16] This data refers to thymalin (bovine polypeptide extract), not the defined thymulin nonapeptide; the relevance to synthetic thymulin combinations is not established.
No peer-reviewed literature specifically characterizes epitalon + thymulin + amlexanox as a combination. Each compound has independent preclinical data; no overlapping safety or pharmacodynamic studies have been published.